SHR-1806 / Jiangsu Hengrui Pharma - LARVOL DELTA

SHR-1806, a robust OX40 agonist to promote T cell-mediated antitumor immunity. (PubMed, Cancer Biol Ther) - "In human OX40 knock-in mice bearing MC38 tumor, SHR-1806 shows a trend toward a higher potency than the reference anti-OX40 antibody produced in-house, GPX4, an analog of pogalizumab, the most advanced drug candidate developed by Roche. Evaluation of SHR-1806 in rhesus monkeys indicates a favorable safety profile and typical pharmacokinetic characteristics. Thus, SHR-1806 emerges as a robust OX40 agonist with promising therapeutic potential."

Journal • Oncology • CD8 • GPX4 • TNFSF4